CN101507715A - 血管紧张素受体抑制剂与氨氯地平的固体制剂及其新的制备方法 - Google Patents
血管紧张素受体抑制剂与氨氯地平的固体制剂及其新的制备方法 Download PDFInfo
- Publication number
- CN101507715A CN101507715A CNA2009101319174A CN200910131917A CN101507715A CN 101507715 A CN101507715 A CN 101507715A CN A2009101319174 A CNA2009101319174 A CN A2009101319174A CN 200910131917 A CN200910131917 A CN 200910131917A CN 101507715 A CN101507715 A CN 101507715A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- valsartan
- sodium carboxymethyl
- carboxymethyl cellulose
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 102000008873 Angiotensin II receptor Human genes 0.000 title claims abstract description 10
- 108050000824 Angiotensin II receptor Proteins 0.000 title claims abstract description 10
- 239000003112 inhibitor Substances 0.000 title claims abstract description 10
- 239000007787 solid Substances 0.000 title claims abstract description 5
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000000080 wetting agent Substances 0.000 claims abstract description 21
- 229940043102 valsartan and amlodipine Drugs 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 7
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 39
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 34
- 229960004699 valsartan Drugs 0.000 claims description 34
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 30
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 21
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 21
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 21
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 17
- 238000004132 cross linking Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 206010013786 Dry skin Diseases 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007779 soft material Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 12
- -1 hydroxypropyl Chemical group 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 229960004005 amlodipine besylate Drugs 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000007891 compressed tablet Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229950004422 hyetellose Drugs 0.000 claims description 2
- 229950005770 hyprolose Drugs 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 238000009492 tablet coating Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000002131 composite material Substances 0.000 claims 1
- 239000007767 bonding agent Substances 0.000 abstract 1
- 239000011812 mixed powder Substances 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 7
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229960002003 hydrochlorothiazide Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229940097420 Diuretic Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- OZCVMXDGSSXWFT-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OZCVMXDGSSXWFT-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940079292 valsartan 40 mg Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101319174A CN101507715B (zh) | 2009-03-17 | 2009-03-27 | 缬沙坦与氨氯地平的固体制剂及其新的制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910119468.1 | 2009-03-17 | ||
CN200910119468 | 2009-03-17 | ||
CN2009101319174A CN101507715B (zh) | 2009-03-17 | 2009-03-27 | 缬沙坦与氨氯地平的固体制剂及其新的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101507715A true CN101507715A (zh) | 2009-08-19 |
CN101507715B CN101507715B (zh) | 2011-11-16 |
Family
ID=41000354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101319174A Expired - Fee Related CN101507715B (zh) | 2009-03-17 | 2009-03-27 | 缬沙坦与氨氯地平的固体制剂及其新的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101507715B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101797250A (zh) * | 2010-04-22 | 2010-08-11 | 重庆市力扬医药开发有限公司 | 一种稳定的复方制剂 |
CN101843615A (zh) * | 2010-06-25 | 2010-09-29 | 包丽昕 | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 |
CN101862328A (zh) * | 2010-06-21 | 2010-10-20 | 天津市汉康医药生物技术有限公司 | 缬沙坦氨氯地平胶囊药物组合物及其制备方法 |
CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
EP2494963A1 (en) * | 2011-03-03 | 2012-09-05 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combinations of valsartan and amlodipine |
CN102697778A (zh) * | 2012-06-21 | 2012-10-03 | 上海医药集团股份有限公司 | 缬沙坦氨氯地平复方固体制剂及其制备方法 |
CN104840460A (zh) * | 2014-02-13 | 2015-08-19 | 长春海悦药业有限公司 | 一种含有缬沙坦和氨氯地平的药物组合物 |
CN105232551A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法 |
CN106176744A (zh) * | 2016-07-13 | 2016-12-07 | 精华制药集团股份有限公司 | 缬沙坦氨氯地平胶囊在制备治疗脑中风的药物中的应用 |
CN108721241A (zh) * | 2017-04-18 | 2018-11-02 | 江苏恒瑞医药股份有限公司 | 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法 |
-
2009
- 2009-03-27 CN CN2009101319174A patent/CN101507715B/zh not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
CN101797250A (zh) * | 2010-04-22 | 2010-08-11 | 重庆市力扬医药开发有限公司 | 一种稳定的复方制剂 |
CN101862328A (zh) * | 2010-06-21 | 2010-10-20 | 天津市汉康医药生物技术有限公司 | 缬沙坦氨氯地平胶囊药物组合物及其制备方法 |
CN101862328B (zh) * | 2010-06-21 | 2012-01-11 | 天津市汉康医药生物技术有限公司 | 缬沙坦氨氯地平胶囊药物组合物及其制备方法 |
CN101843615A (zh) * | 2010-06-25 | 2010-09-29 | 包丽昕 | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 |
EP2494963A1 (en) * | 2011-03-03 | 2012-09-05 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combinations of valsartan and amlodipine |
CN102697778A (zh) * | 2012-06-21 | 2012-10-03 | 上海医药集团股份有限公司 | 缬沙坦氨氯地平复方固体制剂及其制备方法 |
WO2013189305A1 (zh) * | 2012-06-21 | 2013-12-27 | 常州制药厂有限公司 | 缬沙坦氨氯地平复方固体制剂及其制备方法 |
US20150352048A1 (en) * | 2012-06-21 | 2015-12-10 | Changzhou Pharmaceutical Factory | Valsartan-amlodipine compound solid preparation and preparation method therefor |
CN104840460A (zh) * | 2014-02-13 | 2015-08-19 | 长春海悦药业有限公司 | 一种含有缬沙坦和氨氯地平的药物组合物 |
CN104840460B (zh) * | 2014-02-13 | 2017-12-01 | 长春海悦药业股份有限公司 | 一种含有缬沙坦和氨氯地平的药物组合物 |
CN105232551A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法 |
CN106176744A (zh) * | 2016-07-13 | 2016-12-07 | 精华制药集团股份有限公司 | 缬沙坦氨氯地平胶囊在制备治疗脑中风的药物中的应用 |
CN108721241A (zh) * | 2017-04-18 | 2018-11-02 | 江苏恒瑞医药股份有限公司 | 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101507715B (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101507715B (zh) | 缬沙坦与氨氯地平的固体制剂及其新的制备方法 | |
JP5110697B2 (ja) | 固形製剤 | |
CN101485657B (zh) | 缬沙坦复方制剂及其制备方法 | |
TW434239B (en) | Eprosartan dihydrate and a process for its production and formulation | |
CN103006649B (zh) | 一种复方制剂缬沙坦氨氯地平片(ⅰ)及其制备方法 | |
CN103211815B (zh) | 一种缬沙坦氨氯地平药物组合物及其制备方法 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN101632678B (zh) | 一种氯沙坦钾氢氯噻嗪组合物及其制备方法 | |
CN101862328B (zh) | 缬沙坦氨氯地平胶囊药物组合物及其制备方法 | |
CN102697778B (zh) | 缬沙坦氨氯地平复方固体制剂及其制备方法 | |
CN101926793B (zh) | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 | |
CN103565807B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN102342944A (zh) | 一种治疗高血压病的药物组合物 | |
CN101987098A (zh) | 一种缬沙坦氨氯地平药物组合物 | |
CN101554381A (zh) | 坎地沙坦酯氢氯噻嗪双层片及其制备方法 | |
CN110237073A (zh) | 一种奥美沙坦酯氨氯地平片及其制备方法 | |
CN101797250A (zh) | 一种稳定的复方制剂 | |
CN102740838B (zh) | 卡维地洛控释剂 | |
WO2019135691A1 (en) | A stable mono-layer solid dosage form containing combination of two active ingredients | |
WO2009017812A2 (en) | Pharmaceutical composition of candesartan | |
CN101756977A (zh) | 阿折地平的缓释制剂及其制备方法 | |
CN103751127A (zh) | 一种新型的替米沙坦口崩片及其制备方法 | |
CN101849940B (zh) | 一种治疗高血压的药物组合物 | |
CN101912390A (zh) | 含厄贝沙坦的药用组合物 | |
CN103705513B (zh) | 一种含有坎地沙坦酯和苯磺酸氨氯地平的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: YAN JIE Effective date: 20120213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120213 Address after: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee after: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee before: Yan Jie |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20180327 |
|
CF01 | Termination of patent right due to non-payment of annual fee |